3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia
48
Precursor Cell Lymphoblastic Leukemia-Lymphoma
40
Lymphoma
40
Myelodysplastic Syndromes
30
Lymphoma, Non-Hodgkin
29
Lymphoma, Large B-Cell, Diffuse
27
Lymphoma, Follicular
27
Leukemia, Myeloid, Acute
26
Leukemia, Myeloid, Chronic-Phase
25
Leukemia, Lymphocytic, Chronic, B-Cell
24
Burkitt Lymphoma
24
Leukemia, Myeloid, Accelerated Phase
23
Lymphoma, Large-Cell, Immunoblastic
22
Multiple Myeloma
20
Hodgkin Disease
20
Myeloproliferative Disorders
19
Lymphoma, Mantle-Cell
18
Lymphoma, B-Cell, Marginal Zone
18
Graft vs Host Disease
18
Blast Crisis
18
Neoplasms, Plasma Cell
17
Leukemia, Myelomonocytic, Chronic
16
Dendritic Cell Sarcoma, Interdigitating
15
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
14
Congenital Abnormalities
14
Recurrence
13
Anemia, Refractory, with Excess of Blasts
13
Primary Myelofibrosis
12
Myelodysplastic-Myeloproliferative Diseases
12
Lymphoma, T-Cell, Cutaneous
10
Interventions
Blood Specimen Collection
2
bavituximab
1
Ursodeoxycholic Acid
1
Surveys and Questionnaires
1
Steroids
1
Spermine Synthase
1
Sorafenib
1
Prednisone
1
Phlebotomy
1
Mycophenolic Acid
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Liquid Biopsy
1
Clinical Protocols
1
Adrenal Cortex Hormones
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hepatitis
×
Methylprednisolone
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled